Akari Therapeutics (NASDAQ:AKTX) Now Covered by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Monday,Benzinga reports. The firm set a “buy” rating and a $1.00 price target on the biopharmaceutical company’s stock. LADENBURG THALM/SH SH’s price objective suggests a potential upside of 244.83% from the company’s previous close.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akari Therapeutics in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $1.60 target price on shares of Akari Therapeutics in a report on Tuesday, September 9th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $2.53.

Akari Therapeutics Stock Up 0.3%

Shares of AKTX stock opened at $0.29 on Monday. The firm’s 50 day moving average price is $0.45 and its two-hundred day moving average price is $0.79. Akari Therapeutics has a 52-week low of $0.22 and a 52-week high of $1.73.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Cresset Asset Management LLC lifted its holdings in Akari Therapeutics PLC (NASDAQ:AKTX) by 4,368.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 822,468 shares of the biopharmaceutical company’s stock after purchasing an additional 804,060 shares during the quarter. Cresset Asset Management LLC owned about 2.52% of Akari Therapeutics worth $831,000 as of its most recent SEC filing. 5.06% of the stock is currently owned by hedge funds and other institutional investors.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.